Share on StockTwits

Research analysts at Tigress Financial assumed coverage on shares of Eli Lilly and (NYSE:LLY) in a report released on Friday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.

Several other analysts have also recently commented on the stock. Analysts at Citigroup Inc. downgraded shares of Eli Lilly and from a “buy” rating to a “neutral” rating in a research note on Thursday. They now have a $68.00 price target on the stock, up previously from $60.00. Separately, analysts at Argus raised their price target on shares of Eli Lilly and from $64.00 to $72.00 in a research note on Tuesday. They now have a “buy” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Eli Lilly and in a research note on Friday, July 25th. They now have a $68.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $64.14.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 250,000 shares of Eli Lilly and stock on the open market in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $63.03, for a total value of $15,757,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Shares of Eli Lilly and (NYSE:LLY) opened at 60.68 on Friday. Eli Lilly and has a one year low of $47.53 and a one year high of $65.70. The stock’s 50-day moving average is $62.28 and its 200-day moving average is $58.97. The company has a market cap of $65.031 billion and a price-to-earnings ratio of 19.39. Eli Lilly and also was the target of a large decline in short interest in July. As of July 15th, there was short interest totalling 19,160,146 shares, a decline of 11.4% from the June 30th total of 21,636,995 shares. Currently, 1.9% of the company’s stock are short sold. Based on an average trading volume of 3,091,827 shares, the days-to-cover ratio is currently 6.2 days.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Thursday, July 24th. The company reported $0.68 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.65 by $0.03. The company had revenue of $4.94 billion for the quarter, compared to the consensus estimate of $4.88 billion. During the same quarter in the prior year, the company posted $1.16 earnings per share. The company’s quarterly revenue was down 16.8% on a year-over-year basis. Analysts expect that Eli Lilly and will post $2.78 EPS for the current fiscal year.

Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.